Phase II trial of topotecan in patients with advanced renal cell carcinoma
- 1 June 1994
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 12 (2) , 143-145
- https://doi.org/10.1007/bf00874445
Abstract
Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.Keywords
This publication has 3 references indexed in Scilit:
- The Current Status of Camptothecin Analogues as Antitumor AgentsJNCI Journal of the National Cancer Institute, 1993
- STRUCTURE-ACTIVITY STUDY OF THE ACTIONS OF CAMPTOTHECIN DERIVATIVES ON MAMMALIAN TOPOISOMERASE-I - EVIDENCE FOR A SPECIFIC RECEPTOR-SITE AND A RELATION TO ANTITUMOR-ACTIVITY1989
- Reporting results of cancer treatmentCancer, 1981